NEU

0.48%

$20.68 neuren pharmaceuticals limited

Neuren - Cracking the $200m m/cap again., page-63

First 63 Last

Share
Profile

Follow
vinmiao

669 Posts.

60

04/09/19

12:35

Post #: 40306536
Share

Originally posted by hottod: ↑

It seems as if an imminent acquisition of Neuren by Acadia is accepted by many here as a fait accompli.

I question both the likelihood and desirability of this occurring, based on the following:

Acadia’s financial position

Acadia’s net loss for the last half year was $140 million. At 30/06/19, Acadia had $74 million cash on hand and $307 million in investment securities. This follows a capital raise of ~$300 million in late 2018. The company says it expects to continue to incur operating losses for the next few years.

Is Acadia likely to be willing to pay the kind of money NEU shareholders might expect?

Does this sound like a sound financial position from which to purchase another loss-making company with no approved products for, say, $500 million?

What would be the reaction of Acadia shareholders?

Acadia’s global capabilities

Acadia has no regulatory experience or sales force outside of the US and has said itself that if it wants to commercialize Nuplazid in markets outside of the US, it will more than likely need to establish one or more strategic alliances.

Furthermore, the company has shown no haste to launch Nuplazid in Europe. It toyed with the idea of submitting a marketing application there three years ago but put that on hold and is yet to revisit the idea.

Therefore, what chance would trofinetide have for a speedy path to market in markets outside of the US?

Acadia’s management of risk

Acadia’s very low upfront, heavily back-ended deal for North American trofinetide rights, though not popular with the market here, does reflect prudent risk management on Acadia’s part.

Acadia management has stated only recently that they believe it’s very important to focus on business development in a disciplined way, as they said they had done to date.

Is Acadia likely to suddenly change its disciplined approach?

How would the US market view this sudden change in approach to managing risk, a change not reflected in Acadia's previous market advice?

Neuren’s stated aims

How would selling the company to Acadia be consistent with Neuren’s guiding principle of “speed to market for the families affected by these debilitating conditions”.

How would selling the company to Acadia be consistent with Neuren’s stated aim of “securing maximum market value recognition for…. trofinetide and NNZ-2591 worldwide.”

Expand

it’s not a given but likely. Although I don’t think it would be over $5 AUD for a full take over.

NEU Price at posting: $2.22 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Talking Australia's very competitive property landscape: Realty Talks

IMR

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

LKE

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

MCT

Metalicity looking for offers on Admiral Bay zinc project

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

GNX

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

FG1

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

There are more pages in this discussion • 45 more messages in this thread...

First 63 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $20.68		Change -0.100(0.48%)		Mkt cap ! $2.643B

Open	High	Low	Value	Volume
$20.50	$20.74	$20.01	$5.091M	247.9K

Buyers (Bids)

No.	Vol.	Price($)
2	156	$20.67

Sellers (Offers)

Price($)	Vol.	No.
$20.68	256	1

View Market Depth

No.	Vol.	Price($)
2	156	20.670
1	985	20.650
1	100	20.600
1	996	20.560
1	5982	20.550

Price($)	Vol.	No.
20.740	50	1
20.750	2085	3
20.790	1004	1
20.830	1004	1
20.870	1004	1

Last trade - 16.10pm 19/07/2024 (20 minute delay)

NEU (ASX) Chart

Neuren - Cracking the $200m m/cap again., page-63

Talking Australia's very competitive property landscape: Realty Talks

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Metalicity looking for offers on Admiral Bay zinc project

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Neuren - Cracking the $200m m/cap again., page-63

Top Stories

Talking Australia's very competitive property landscape: Realty Talks

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Metalicity looking for offers on Admiral Bay zinc project

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

AI stocks: What to expect in 2024-25

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News